--- title: "Ausun Pharm: Imatinib Mesylate Tablets Obtained Drug Registration Certificate" type: "News" locale: "en" url: "https://longbridge.com/en/news/257494262.md" description: "Ausun Pharm's wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., has obtained the Drug Registration Certificate for Imatinib Mesylate Tablets issued by the National Medical Products Administration. This drug is the world's first molecular targeted therapy for tumors, primarily used to treat chronic myeloid leukemia and malignant gastrointestinal stromal tumors. The active ingredient, Imatinib, is a tyrosine kinase inhibitor that can inhibit the proliferation of abnormal white blood cells" datetime: "2025-09-16T08:15:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/257494262.md) - [en](https://longbridge.com/en/news/257494262.md) - [zh-HK](https://longbridge.com/zh-HK/news/257494262.md) --- # Ausun Pharm: Imatinib Mesylate Tablets Obtained Drug Registration Certificate According to the Zhitong Finance APP, Ausun Pharm (603229.SH) announced that its wholly-owned subsidiary Zhejiang Qizheng Pharmaceutical Co., Ltd. (referred to as "Qizheng Pharmaceutical") has received the Drug Registration Certificate for Imatinib Mesylate Tablets issued by the National Medical Products Administration. The announcement shows that Imatinib Mesylate Tablets are the world's first molecular targeted drug for anti-tumor treatment, used for patients in the chronic phase after the acute phase or accelerated phase of chronic myeloid leukemia (CML) or those who have failed α-interferon treatment, as well as patients with malignant gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have metastasized. Its active ingredient, imatinib, is a tyrosine kinase inhibitor that can effectively inhibit the Philadelphia chromosome gene, preventing the phosphorylation reaction from being catalyzed and leading to the loss of chromosome function, thereby inhibiting the abnormal proliferation of white blood cells; it can also bind to the active site of tyrosine kinase and block its activity ### Related Stocks - [603229.CN](https://longbridge.com/en/quote/603229.CN.md) ## Related News & Research - [TRUMP ON UFO FILES: WE WILL DECLASSIFY AS MUCH AS POSSIBLE GOING FORWARD.](https://longbridge.com/en/news/284625392.md) - [RFK Jr.'s New Autism Committee Issues First Proposals](https://longbridge.com/en/news/284480897.md) - [](https://longbridge.com/en/news/284610260.md) - [Purdue Pharma to be sentenced, paving way for opioid settlement](https://longbridge.com/en/news/284356869.md) - [07:16 ETChina's Yangtze River Pharmaceutical Group Expands Global Footprint as Quality Drives Growth](https://longbridge.com/en/news/284557182.md)